{"filing":{"accession_number":"0001104659-26-102917","cik":"0001671502","ticker":"QNRX","company_name":"Quoin Pharmaceuticals, Ltd.","form":"8-K","filing_date":"2026-08-28","report_date":"2026-08-27","primary_document":"tm2624258d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926102917/tm2624258d1_8k.htm"},"events":[{"id":30243,"run_id":27723,"accession_number":"0001104659-26-102917","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Quoin entered into a Securities Purchase Agreement on August 27, 2026, for a private placement of up to $50.0 million in gross proceeds, consisting of 6,305,300 ADSs (or pre-funded warrants) and accompanying ordinary warrants to purchase 3,152,650 ADSs. The unregistered equity issuance under Section 4(a)(2) and Regulation D exemptions is structured as a PIPE-like transaction with insider participation, representing significant dilution to existing shareholders and expected to fund operations into the second half of 2029.","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-08-28","form":"8-K","submitted_at":null,"items":[{"id":32791,"accession_number":"0001104659-26-102917","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Quoin entered into a Securities Purchase Agreement on August 27, 2026, for a private placement of up to $50.0 million in gross proceeds, consisting of 6,305,300 ADSs (or pre-funded warrants) and accompanying ordinary warrants to purchase 3,152,650 ADSs. This is an unregistered equity issuance under Section 4(a)(2) of the Securities Act, structured as a PIPE-like transaction with warrants. The filing explicitly discloses that insider directors and officers participated, purchasing 57,370 ADSs for approximately $280,000. The transaction is material to equity holders as it represents significant dilution and is a primary capital-raising event for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T14:31:51.359073+00:00","company_name":"","ticker":null,"filing_date":""},{"id":32792,"accession_number":"0001104659-26-102917","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered private placement (PIPE) of up to $50 million in gross proceeds, including 6,305,300 ADSs (or pre-funded warrants) and 3,152,650 ordinary warrants. The securities are being issued under Section 4(a)(2) and Regulation D exemptions to qualified institutional buyers and accredited investors. This is a classic dilutive equity issuance raising capital through unregistered securities, with the press release confirming the financing is expected to fund operations into the second half of 2029.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T14:31:51.359073+00:00","company_name":"","ticker":null,"filing_date":""},{"id":32793,"accession_number":"0001104659-26-102917","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The primary disclosure in Item 7.01 is the announcement of a private placement financing of up to $50.0 million through issuance of 6,305,300 ADSs (or pre-funded warrants) and accompanying ordinary warrants. This is a classic dilutive equity issuance under Section 4(a)(2) of the Securities Act. While the Item 7.01 also references positive interim clinical trial results (Exhibit 99.2), the substantive filing action centers on the securities offering, making dilutive_issuance the most appropriate classification. The positive clinical data appears to be furnished as supporting context for investor confidence in the financing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T14:31:51.359073+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":30244,"run_id":27723,"accession_number":"0001104659-26-102917","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Quoin announced positive interim clinical trial results from the Phase 2/3 study CL-QRX003-004 of QRX003 for Netherton Syndrome, with the primary endpoint met with statistical significance (p=0.0087 vs. α=0.0215) in 4 of 6 participants. This material clinical milestone represents a significant development in the company's late-stage specialty pharmaceutical pipeline.","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-08-28","form":"8-K","submitted_at":null,"items":[{"id":32794,"accession_number":"0001104659-26-102917","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The Item 8.01 disclosure centers on positive interim clinical trial results from the Phase 2/3 study CL-QRX003-004 of QRX003 for Netherton Syndrome, with the primary endpoint met with statistical significance (p=0.0087 vs. α=0.0215) in 4 of 6 participants. While clinical trial progress is operationally significant for a late-stage specialty pharmaceutical company and would materially affect investor assessment of the registrant's pipeline prospects, this does not fit the specific event types (e.g., earnings_release, which typically reports financial results). The disclosure is a material clinical milestone announcement rather than a financial result, making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T14:31:51.359073+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32791,"accession_number":"0001104659-26-102917","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Quoin entered into a Securities Purchase Agreement on August 27, 2026, for a private placement of up to $50.0 million in gross proceeds, consisting of 6,305,300 ADSs (or pre-funded warrants) and accompanying ordinary warrants to purchase 3,152,650 ADSs. This is an unregistered equity issuance under Section 4(a)(2) of the Securities Act, structured as a PIPE-like transaction with warrants. The filing explicitly discloses that insider directors and officers participated, purchasing 57,370 ADSs for approximately $280,000. The transaction is material to equity holders as it represents significant dilution and is a primary capital-raising event for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T14:31:51.359073+00:00","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-08-28"},{"id":32792,"accession_number":"0001104659-26-102917","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered private placement (PIPE) of up to $50 million in gross proceeds, including 6,305,300 ADSs (or pre-funded warrants) and 3,152,650 ordinary warrants. The securities are being issued under Section 4(a)(2) and Regulation D exemptions to qualified institutional buyers and accredited investors. This is a classic dilutive equity issuance raising capital through unregistered securities, with the press release confirming the financing is expected to fund operations into the second half of 2029.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T14:31:51.359073+00:00","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-08-28"},{"id":32793,"accession_number":"0001104659-26-102917","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The primary disclosure in Item 7.01 is the announcement of a private placement financing of up to $50.0 million through issuance of 6,305,300 ADSs (or pre-funded warrants) and accompanying ordinary warrants. This is a classic dilutive equity issuance under Section 4(a)(2) of the Securities Act. While the Item 7.01 also references positive interim clinical trial results (Exhibit 99.2), the substantive filing action centers on the securities offering, making dilutive_issuance the most appropriate classification. The positive clinical data appears to be furnished as supporting context for investor confidence in the financing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T14:31:51.359073+00:00","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-08-28"},{"id":32794,"accession_number":"0001104659-26-102917","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The Item 8.01 disclosure centers on positive interim clinical trial results from the Phase 2/3 study CL-QRX003-004 of QRX003 for Netherton Syndrome, with the primary endpoint met with statistical significance (p=0.0087 vs. α=0.0215) in 4 of 6 participants. While clinical trial progress is operationally significant for a late-stage specialty pharmaceutical company and would materially affect investor assessment of the registrant's pipeline prospects, this does not fit the specific event types (e.g., earnings_release, which typically reports financial results). The disclosure is a material clinical milestone announcement rather than a financial result, making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T14:31:51.359073+00:00","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-08-28"}]}